enGene Therapeutics Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ENGN Nasdaq 2830 www.engene.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for enGene Therapeutics Inc.

enGene to Host Virtual KOL Event to Discuss Emerging Non-Muscle Invasive Bladder Cancer (NMIBC) Market Insights, on August 11, 2026 - Aug 4th, 2026 6:00 am
enGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones - Jul 16th, 2026 6:00 am
Rectify Pharmaceuticals Announces Appointment of Constantine Chinoporos as Executive Chairman - Jul 15th, 2026 7:00 am
Neumora depression drug fails; EnGene to cut 50% of staff - Jun 16th, 2026 3:08 am
A Look At enGene Therapeutics (ENGN) Valuation After LEGEND Trial Update And Legal Investigations - May 10th, 2026 7:11 pm
enGene Bladder Cancer Data Shows Promise, but Durability Questions Remain - May 8th, 2026 5:05 pm
enGene Therapeutics (ENGN) Is Down 76.3% After Mixed LEGEND Phase 2 Durability Data Release Has The Bull Case Changed? - May 8th, 2026 3:27 pm
enGene Therapeutics hit by analyst downgrades as drug data disappoints - May 8th, 2026 9:41 am
enGene Shares Detalimogene NMIBC Trial Changes, FDA Endpoint Shift, and 2027 Approval Path at Conference - Mar 15th, 2026 3:33 pm
enGene Highlights 2026 Data Catalysts, BLA Plans for Bladder Cancer Gene Therapy at Barclays Conference - Mar 15th, 2026 2:37 pm
enGene CEO Pitches Detalimogene as Community-Friendly NMIBC Option, Teases Q2 LEGEND Data Update - Mar 15th, 2026 1:03 pm
enGene Maps BLA by End-2026, Targets 2027 Launch for Lead NMIBC Therapy at Oppenheimer Conference - Feb 27th, 2026 5:16 pm
Jefferies Sets a $28 PT for enGene Holdings Inc. (ENGN) - Feb 16th, 2026 5:04 am
enGene CEO Talks Detalimogene for Community Urology as LEGEND Study Hits Full Enrollment - Feb 12th, 2026 3:02 am
Both private equity firms who control a good portion of enGene Holdings Inc. (NASDAQ:ENGN) along with institutions must be dismayed after last week's 16% decrease - Feb 2nd, 2026 3:50 am
Spotify upgraded, Pinterest downgraded: Wall Street's top analyst calls - Jan 30th, 2026 7:54 am
Specific Biologics Welcomes Accomplished Biotechnology Leader Dr. Richard Glickman to its Board of Directors - Dec 16th, 2025 8:00 am
enGene Holdings Inc (ENGN) Surging After Positive Phase 2 LEGEND Trial - Dec 4th, 2025 8:09 pm
enGene Holdings (ENGN) Is Up 36.9% After Strong Phase 2 Bladder Cancer Gene Therapy Results - Nov 13th, 2025 1:17 am
enGene’s NMIBC gene therapy touts 63% complete response in pivotal trial - Nov 11th, 2025 10:04 am